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FUNCTIONAL RENAL INVOLVEMENT IN 
NORMOTENSIVE PATIENTS WITH 
PROGRESSIVE SYSTEMIC SCLEROSIS 
Impaired Sodium Excretion during Isotonic Saline Infusion 
A. D'ANGELO, P. MESSA, U. FIOCCO, A. FABRIS, P. MORACHIELLO, 
G. SENESI, and S. TODESCO 
An intravenous infusion of 2,000 ml isotonic sa- 
line was performed in 8 normotensive, normoreninemic 
patients with progressive systemic sclerosis. None of 
them had clinical evidence of renal disease. Total and 
proximal fractional excretion of sodium was reduced 
when compared with that of 8 normal subjects. No cor- 
relation was found with para-aminohippurate (PAH) 
clearance values. Two years after this study was done, 4 
patients developed arterial hypertension; interestingly, 
plasma renin activity remained within the normal range. 
Reduced sodium excretion is suggested as having a 
pathogenetic role in the hypertension of progressive sys- 
temic sclerosis. 
Since the report by Moore and Sheehan ( I ) ,  in- 
creasing evidence has been obtained that renal in- 
volvement is a very important feature of progressive 
systemic sclerosis (PSS) or scleroderma and is one of the 
most prominent causes of death in the affected patients 
It is also well known that arterial hypertension, 
often in its malignant form, is a manifestation of renal 
involvement in PSS (4). 
Hyperreninemia has been frequently reported in 
PSS hypertensive patients (7-9). It has been suggested 
(2-6). 
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that renin not only causes hypertension through angio- 
tensin activation, but it also promotes vasoconstriction 
and vascular damage, which further leads to the malig- 
nant phase of hypertension and rapidly progressive 
renal failure (10- 13). Conversely, sodium metabolism, 
which is intimately related to hypertension in renal dis- 
eases, has received little attention in PSS. 
To investigate the possible role of an early de- 
rangement of renal handling of sodium in PSS, a group 
of normoreninemic patients with scleroderma who had 
neither hypertension nor clinical evidence of renal dis- 
ease was studied by means of an acute isotonic saline in- 
fusion in maximal water diuresis. 
PATIENTS AND METHODS 
Eight patients (5 women and 3 men aged 18-65 years) 
afflicted with PSS were studied. The criteria for diagnosis of 
PSS were defined as the presence of diffuse skin induration 
(diffuse scleroderma), Raynaud's phenomenon, and esopha- 
geal and pulmonary involvement as assessed by radiology. 
None had CREST syndrome. The duration of symptoms 
ranged from 6 to 41 years. 
At the time of our study, none of these patients had a 
diastolic pressure above 8 0  mmHg or a systolic blood pressure 
above 140 mmHg; in all of them cardiac index and plasma re- 
nin activity (PRA) were within the normal range. PRA was 
determined by radioimmunoassay of generated angiotensin I 
(14) in blood samples collected both in supine and standing 
positions. 
No evidence of renal damage was present, as eval- 
uated by urinalysis, creatinine clearance, BUN values, con- 
centration, and acidification tests performed according to the 
standard procedures (1 5). A urinary osmolality of more than 
800 mOsm/kg water and a urine pH of less than 5.3 units 
were considered the normal limits for concentration and acid- 
ification studies (1 5) .  
All drugs (griseofulvin, vasodilators, and nonsteroidal 
antiinflammatory compounds) were discontinued at least 15 
days prior to the study. 
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Eight normal subjects were used as controls. Both pa- 
tients and controls were kept on a constant diet containing 
150 mEq of Na' and C1- prior to the study. 
After an overnight fast, 10 mg of deoxycorticosterone 
acetate were injected intramuscularly. Then a hypotonic max- 
imal diuresis was induced by giving 20 ml/kg of tap water and 
maintained by additional amounts of water equal to the uri- 
nary losses. When urinary osmolality was below 70 mOsm/kg 
water, 2,000 ml of isotonic saline were infused intravenously 
over 150 minutes, and five clearance periods were obtained, 
during which the different patterns of Na' transport along the 
nephron were calculated according to Seldin and Rector (16). 
Before and after the saline infusion, inuline and PAH 
clearances were performed according to Roe (17) and Smith 
(18). In plasma and urine, sodium and potassium concentra- 
tions were determined by atomic absorption spectrophotome- 
ter (Perkin-Elmer model 370); chloride levels were assessed by 
titrimetic method (Oxford titrator) and osmolality by freezing 
point depression with Halmikro-Osmometer. 
The urine pH was evaluated by means of pH-meter 
(Radiometer-Copenhagen). 
RESULTS 
In all patients, inulin clearances were above 90 
ml/minute. PAH clearances were within the normal 
range (550-650 ml/minute) in 3 patients and below 350 
ml/minute in 5 patients, with the filtration fraction (FF) 
ranging 0.17 to 0.31. 
Table 1 shows the results of volume expansion in 
the group of sclerodermic patients compared with con- 
trols. The values are expressed as mean +- SEM. 
The urine output and fractional excretion of so- 
dium (FEN,) were significantly reduced in PSS patients 
(Table 1). Proximal fractional excretion of sodium 
(PFEN,) appeared even more significantly depressed in 
the same group of patients (Table 1). 
Free water clearance (C,,,), an indirect estima- 
tion of sodium reabsorption in the ascending limb of 
Henle's loop, was lower in PSS patients than in controls 
(Table 1). However, when CHZ, values were corrected 
by distal delivery of sodium, using the chloride clear- 
ance (16), no difference was evident. 
Distal sodium reabsorption, roughly estimated 
by fractional excretion of potassium (FE,), did not 
show any significant difference. 
The mean values of total sodium excretion dur- 
ing the infusion of a solution containing 308 mEq of 
Na' were significantly lower in patients with PSS than 
in controls (40.95 f 7.58 and 107.62 f 20.07 mEq, re- 
spectively; t = 3.107, P < 0.01). 
After this study was performed, a reliable fol- 
lowup was obtained in all 8 patients for 2 years. Up to 
now, 4 of the 8 patients have developed hypertension, 
and repeated testing of PRA levels on these patients re- 
ceiving a constant diet containing 150 mEq of Na' and 
C1V have been within normal limits (Table 2). 
Table 2 summarizes each patient's values of 
PAH clearance and PRA determinations before the sa- 
line infusion, the sodium retention as a percentage of 
Table 1. The effect of saline load in 8 PSS patients and 8 normal subjects 
V/GFR X l00t CHp/GFR x 100f FENa%§ P F E ~ ,  en 



















3.58f0.98 3.04f0.52 1.62f 1.04 0.95k0.44 
0.485 0.584 
NS NS 
7.55f1.05 11.22fl.84 5.07f0.88 7.25f1.35 
1.733 1.353 
NS NS 
9.15 f 1.48 13.77 f 1.04 6.91 f 1.30 10.03 k 0.90 
2.559 1.974 
t0.025 NS 
9.61 f 1.41 14.74 k 0.58 6.84 f 1.05 11.02 f 0.53 
3.367 3.556 
t0.005 t0.005 
8.57f1.51 15.62f0.43 5.97f 1.38 11.65fO.29 
4.496 4.030 
tO.OO1 to.001 
10.36f 1.88 16.22f0.82 7.37f 1.35 11.69fO.60 
2.856 3.847 
t0.02 (0.005 
1.02 * 0.27 1.30 f 0.24 3.31 f 1.22 2.71 f 0.55 
0.775 0.448 
NS NS 
1.2020.21 5.30f2.63 6.702 1.05 13.23k2.73 
2.495 2.232 
t0.025 t0.05 
1.43 f 0.31 3.94 f 0.80 8.74 k 1.56 14.61 f 0.97 
2.925 3.195 
1.81 f 0.43 5.54 f 0.83 9.05 f 1.17 17.22 f 1.22 
3.990 4.833 
t0.005 t O . 0 0 1  
2.45 k 0.51 6.06 f 2.24 8.83 rt 1.67 18.44 k 2.30 
1.57 1 3.381 
NS t0.005 
2.15 f 0.42 4.89 f 0.98 10.05 f 1.72 17.28 f 1.41 
2.570 3.251 
to.01 to.0 I 
t0.025 t O . O 1  
* Values expressed are mean f SEM. 
t V/GFR = urine volume per minute/glomerular filtration rate. 
f CH20 = free water clearance. 
5 FEN, = fractional excretion of sodium. 
7 PFEN, = proximal fractional excretion of sodium. 
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Table 2. Functional and clinical data in 8 PSS patients 
Subsequent 
PRAS development PRA, after 2 years 
Name Sex (ml/min)* retentiont Supineg Standing1 hypertension Supine Standing 
BM F 305 82.49 1.90 3.30 Yes 2.05 4.18 
DA M 585 80.10 2.00 3.06 Yes 1.83 3.02 
DM M 610 94.97 2.10 3.60 No 
LF M 340 89.33 0.93 2.13 No 
SA F 315 83.72 1.30 3.40 Yes 2.00 3.10 
SL F 325 78.64 2.26 3.46 No 
VA F 650 86.36 0.30 0.60 No 
* ClpAH = para-aminohippurate clearance. 
t As a percentage of sodium infused during the test time. + PRA = plasma renin activity. 
5 Normal range 0.2-2.7 ng/ml/hour. 
7 Normal range 1.5-5.6 ng/ml/hour. 
ClpAH Sodium of 
TA F 345 98.05 0.70 1.00 Yes 1.44 2.80 
sodium infused, and the subsequent development of hy- 
pertension. No correlation was found among these pa- 
rameters. 
DISCUSSION 
It has been suggested that the intrarenal vascular 
changes might play a predominant role in the pathogen- 
esis of hyperreninemia in progressive systemic sclerosis 
(4,5,7). Indeed, in sclerodermic patients with severe hy- 
pertension or renal failure, high renin levels are often 
observed (7-9), and there is strong evidence that the re- 
nin-angiotensin system may play a significant patho- 
genetic role in the acceleration of renal damage (10-12). 
Nevertheless, during preclinical renal in- 
volvement in PSS, the role of hyperreninemia in caus- 
ing high blood pressure is at present still debatable, and 
in nonmalignant hypertension high values of PRA are 
not usually found ( 10,19-2 1). 
Moreover, vascular renal lesions such as hyaline 
sclerosis, intimal fibrosis, and fibrinoid degeneration 
have been described before any increase in serum renin 
level (14). 
In a group of normoreninemic sclerodermic pa- 
tients with normal blood pressure, we found an in- 
adequate natriuretic response to saline infusion, both in 
those with normal and those with reduced PAH clear- 
ance. This early renal sodium retention, which is evi- 
dent in spite of the absence of clinical signs of renal 
damage, has been observed years before the develop- 
ment of arterial hypertension. 
Our results are consistent with the view that so- 
dium retention probably takes place before renin-an- 
giotensin system activation, and therefore it should be 
considered the prominent underlying pathogenetic 
mechanism of nonmalignant hypertension in sclero- 
derma. Such a metabolic disorder is not regularly corre- 
lated with PAH clearance values, which are usually 
considered an early index of renal involvement in PSS 
(22), and might represent the first appearance of abnor- 
mal renal function in this disease. 
The impaired natriuresis in our patients seems to 
be due to an exaggerated sodium reabsorption in the 
proximal tubule. The various factors affecting water and 
solute reabsorption in the proximal tubule include 
glomerulotubular balance, peritubular capillary forces, 
sympathetic nerve activity, and some unidentified na- 
triuretic factor(s), presumably hormonal, that inhibit so- 
dium or chloride reabsorption or both at one or several 
nephron sites and increased sodium excretion (23,24). 
Our data do not indicate which of these factors 
are mainly involved in our patients. Moreover, since so- 
dium reabsorption was not correlated with PAH clear- 
ance or filtration fraction, such hemodynamic parame- 
ters do not seem to be responsible for the impaired 
natriuresis. 
Conversely, it cannot be excluded that a lack of 
activity of some natriuretic substances (such as natri- 
uretic hormone or third factor (25), prostaglandins, kal- 
likrein, kinins, and dopamine) may be implicated in the 
pathogenesis of sodium retention. 
Plasma renin levels remained within the normal 
range in our patients, regardless of the eventual devel- 
opment of benign hypertension in 50% of them. 
It has been suggested that in the preclinical 
stages of renal disease in PSS sodium retention might 
cause inhibition of renin release in spite of renal under- 
perfusion, which could be the case in the 4 patients who 
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developed mild hypertension. On the contrary, the renin 
release, which is increased in the great majority of PSS 
patients with malignant or accelerated hypertension, 
seems to become independent of the degree of sodium 
retention owing to the severe renal vascular disease (2 1). 
This study in scleroderma patients with normal 
arterial pressure demonstrates inadequate sodium ex- 
cretion after saline infusion. Further studies in the early 
phase of hypertension in scleroderma may determine 
whether our data support the hypothesis that renal al- 
terations can cause hypertension through an inadequate 
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